AJH: Single-dose versus low-dose rituximab for corticosteroid-resistant or recurrent ITP: a multicenter, randomized, controlled study

In primary immune thrombocytopenia (ITP), an autoimmune bleeding disorder, rituximab (RTX) induced the best long-term effects among the recommended second-line therapy
.

However, the optimal treatment regimen for rituximab remains unclear

In primary immune thrombocytopenia (ITP), an autoimmune bleeding disorder, rituximab (RTX) induced the best long-term effects among the recommended second-line therapy

Figure 1: Study Design and Treatment Disposition
.

Figure 1: Study Design and Treatment Disposition
.

Table 1: Demographic and baseline characteristics of patients
.

Data are n (%) or median (range) unless otherwise stated

Table 1: Demographic and baseline characteristics of patients

Patients recruited by the study team were randomly assigned (1:1) to receive repeated low-dose RTX (100 mg weekly for 4 weeks, LD-RTX) or a single dose (375 mg/m ² , S-RTX)

Figure 2: Kaplan-Meier response duration curves for patients with initial response (including CR and R)
.

Kaplan-Meier curves showed that the overall duration of response was similar in the two groups throughout the follow-up period

Figure 2: Kaplan-Meier response duration curves for patients with initial response (including CR and R)

In terms of health-related quality of life, S-RTX improved patients' psychological status, quality of life, social activities, and work compared with LD-RTX

Table 2: Responses and results of the LD-RTX group and the S-RTX group
.

Data are presented as n (%) patients

Table 2: Responses and results of the LD-RTX group and the S-RTX group

In conclusion, the results of this study suggest that a single infusion of 375 mg/m2 ^of RTX is safe and effective, similar to the efficacy of low-dose RTX for corticosteroid-resistant or relapsed ITP

Original source:

Original source:

Ni, X ,Li, D ,Yuan, C , et al.
Single-dose versus low-dose rituximab in corticosteroid-resistant or relapsed ITP: A multicenter, randomized, controlled study .
AmJ Hematol .
2022; 1-8.
doi : 10.
1002/ajh.
26473

Ni, X ,  Li, D ,  Yuan, C , et al.
  Single-dose versus low-dose rituximab in corticosteroid-resistant or relapsed ITP: A multicenter, randomized, controlled study .
  Am  J Hematol .
2022  ; 1-8  .
doi : 10.
1002/ajh.
26473 Ni, X ,  Li, D ,  Yuan, C , et al.
  Single-dose versus low-dose rituximab in corticosteroid-resistant or relapsed ITP: A multicenter, randomized, controlled study .
  Am J Hematol .
  2022 ;  1 -  8.
doi: 10.
1002/ajh.
26473leave a message here